Cargando…

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria

BACKGROUND: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD and type 2 diabetes mellitus in FIDELIO-DKD, where 5734 patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goulooze, Sebastiaan Camiel, Snelder, Nelleke, Seelmann, Andreas, Horvat-Broecker, Andrea, Brinker, Meike, Joseph, Amer, Garmann, Dirk, Lippert, Joerg, Eissing, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891103/ https://www.ncbi.nlm.nih.gov/pubmed/34786651 http://dx.doi.org/10.1007/s40262-021-01083-1

Ejemplares similares

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis
por: van den Berg, Paul, et al.
Publicado: (2021)

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
por: Chiu, Nicholas, et al.
Publicado: (2022)

Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials
por: Flack, John M., et al.
Publicado: (2023)

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
por: Snelder, Nelleke, et al.
Publicado: (2019)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study
por: Rossing, Peter, et al.
Publicado: (2022)

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
por: Rossing, Peter, et al.
Publicado: (2021)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

Fidelio /
por: Beethoven, Ludwig van, 1770-1827
Publicado: (1985)

Fidelio Ponce
por: Sánchez, Juan
Publicado: (1985)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
por: Filippatos, Gerasimos, et al.
Publicado: (2021)

The FIDELIO Study Podcast
por: Toto, Robert, et al.
Publicado: (2022)

Correction to: The FIDELIO Study Podcast
por: Toto, Robert, et al.
Publicado: (2022)

Dose/exposure–response modeling in dose titration trials: Overcoming the titration paradox
por: Kristensen, Niels Rode, et al.
Publicado: (2022)

Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk
por: Scilletta, Sabrina, et al.
Publicado: (2023)

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
por: Wendl, Thomas, et al.
Publicado: (2021)

Detection of DKD stage 1 and treatment are essential
por: Futrakul, Narisa, et al.
Publicado: (2018)

Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis
por: Pitt, Bertram, et al.
Publicado: (2022)

Role of Sphingolipid Signaling in Glomerular Diseases: Focus on DKD and FSGS
por: Mitrofanova, Alla, et al.
Publicado: (2020)

The role of lncRNAs in regulation of DKD and diabetes-related cancer
por: Cheng, Yawei, et al.
Publicado: (2022)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials
por: Norris, David C.
Publicado: (2017)

2DKD: a toolkit for content-based local image search
por: DeVille, Julian S., et al.
Publicado: (2020)

Virtual Patient Simulation in DKD: Successful Strategy for Improving Recognition and Management
por: Larkin, Amy, et al.
Publicado: (2021)

Network Pharmacology-Based Prediction of Mechanism of Shenzhuo Formula for Application to DKD
por: Wang, Xinmiao, et al.
Publicado: (2021)

P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol
por: Thorpy, M, et al.
Publicado: (2021)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study
por: Reif, Stefanie, et al.
Publicado: (2013)

Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database
por: Wanner, Christoph, et al.
Publicado: (2022)

Titration of amlodipine to higher doses: a comparison of Asian and Western experience
por: Kario, Kazuomi, et al.
Publicado: (2013)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Lessons learned from two randomized controlled trials: CITIES and STOP-DKD
por: Zullig, Leah L., et al.
Publicado: (2020)

ODP223 Metabolic efficacy of Very Low Carbohydrate Diet in DKD patients
por: Zainordin, Nur Aisyah, et al.
Publicado: (2022)

Both sexes develop DKD in the CD1 uninephrectomized streptozotocin mouse model
por: Trink, Jackie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bd8v03u4mjoavi7f7emin7kttp